 Avalon GloboCare Corp NASDAQ:AVCO has reached a definitive agreement to acquire Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in terms of biomanufacturing scale, breadth and depth of clinical development programs, and pre-clinical research. SenlangBios core technology platforms include chimeric antigen receptor CAR T-cells CAR-T, allogeneic CAR Gamma Delta T-cells CAR-γδT, and armored tumor infiltrating lymphocytes armTILs, the company said. 